Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IOVA Iovance Biotherapeutics	$1.69 -2.9%	$2.30	$1.64 ▼ $12.51	$581.05M	0.86	9.05 million shs	17.46 million shs
NUVB Nuvation Bio	$1.94 -1.4%	$2.15	$1.54 ▼ $3.97	$670.32M	1.37	2.92 million shs	14.17 million shs
NVCT Nuvectis Pharma	$7.55 -2.1%	$9.15	$4.44 ▼ $11.80	$161.09M	-0.16	136,361 shs	1.87 million shs
URGN Urogen Pharma	$13.49 +2.9%	$9.34	$3.42 ▼ $18.15	$604.47M	0.4	1.07 million shs	2.27 million shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IOVA Iovance Biotherapeutics	-2.87%	-14.65%	-3.43%	-52.53%	-79.16%
NUVB Nuvation Bio	-0.66%	-0.66%	-11.32%	+7.00%	-35.05%
NVCT Nuvectis Pharma	-2.08%	-7.13%	-21.84%	-27.82%	+16.15%
URGN Urogen Pharma	+2.90%	-7.92%	+233.09%	+20.45%	-21.48%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
IOVA Iovance Biotherapeutics	4.6671 of 5 stars	4.3	1.0	4.2	1.8	4.2	1.3
NUVB Nuvation Bio	3.5447 of 5 stars	4.6	0.0	0.0	3.1	5.0	0.0
NVCT Nuvectis Pharma	2.9791 of 5 stars	3.5	0.0	0.0	3.0	5.0	0.6
URGN Urogen Pharma	4.5832 of 5 stars	4.5	2.0	4.5	2.9	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IOVA Iovance Biotherapeutics	2.50	Moderate Buy	$12.22	623.21% Upside
NUVB Nuvation Bio	3.20	Buy	$7.17	269.04% Upside
NVCT Nuvectis Pharma	3.00	Buy	$17.00	125.17% Upside
URGN Urogen Pharma	3.00	Buy	$32.86	143.57% Upside

Current Analyst Ratings Breakdown

Latest NVCT, URGN, NUVB, and IOVA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/25/2025	NUVB Nuvation Bio	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$6.00
6/17/2025	NUVB Nuvation Bio	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$10.00 ➝ $6.00
6/16/2025	URGN Urogen Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$50.00
6/13/2025	URGN Urogen Pharma	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Neutral ➝ Neutral	$16.00
6/13/2025	URGN Urogen Pharma	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Buy	$31.00
6/13/2025	URGN Urogen Pharma	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
6/13/2025	URGN Urogen Pharma	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Outperform ➝ Sector Outperform	$23.00 ➝ $47.00
6/13/2025	URGN Urogen Pharma	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $30.00
6/12/2025	URGN Urogen Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
6/11/2025	NUVB Nuvation Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$5.00
6/3/2025	URGN Urogen Pharma	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$36.00 ➝ $10.00

(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IOVA Iovance Biotherapeutics	$164.07M	3.44	N/A	N/A	$2.33 per share	0.73
NUVB Nuvation Bio	$7.87M	83.96	N/A	N/A	$1.37 per share	1.42
NVCT Nuvectis Pharma	N/A	N/A	N/A	N/A	$0.50 per share	N/A
URGN Urogen Pharma	$90.40M	6.88	N/A	N/A	($0.21) per share	-64.24

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IOVA Iovance Biotherapeutics	-$372.18M	-$1.24	N/A	N/A	N/A	-176.49%	-49.71%	-39.18%	8/6/2025 (Estimated)
NUVB Nuvation Bio	-$567.94M	-$2.35	N/A	N/A	N/A	-5,534.21%	-44.14%	-32.97%	8/4/2025 (Estimated)
NVCT Nuvectis Pharma	-$19M	-$1.13	N/A	N/A	N/A	N/A	-148.83%	-95.60%	8/5/2025 (Estimated)
URGN Urogen Pharma	-$126.87M	-$3.18	N/A	N/A	N/A	-150.68%	-97,487.15%	-49.57%	8/12/2025 (Estimated)

Latest NVCT, URGN, NUVB, and IOVA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	URGN Urogen Pharma	-$0.83	-$0.92	-$0.09	-$0.92	$22.71 million	$20.25 million
5/8/2025	Q1 2025	IOVA Iovance Biotherapeutics	-$0.25	-$0.36	-$0.11	-$0.36	$83.40 million	$49.32 million
5/7/2025	Q1 2025	NUVB Nuvation Bio	-$0.16	-$0.16	N/A	-$0.16	$0.42 million	$3.08 million
5/6/2025	Q1 2025	NVCT Nuvectis Pharma	-$0.30	-$0.27	+$0.03	-$0.27	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IOVA Iovance Biotherapeutics	N/A	N/A	N/A	N/A	N/A
NUVB Nuvation Bio	N/A	N/A	N/A	N/A	N/A
NVCT Nuvectis Pharma	N/A	N/A	N/A	N/A	N/A
URGN Urogen Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IOVA Iovance Biotherapeutics	N/A	4.18	3.64
NUVB Nuvation Bio	N/A	9.01	9.01
NVCT Nuvectis Pharma	N/A	3.28	3.28
URGN Urogen Pharma	4.77	5.65	5.47

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IOVA Iovance Biotherapeutics	77.03%
NUVB Nuvation Bio	61.67%
NVCT Nuvectis Pharma	96.77%
URGN Urogen Pharma	91.29%

Insider Ownership

Company	Insider Ownership
IOVA Iovance Biotherapeutics	10.30%
NUVB Nuvation Bio	29.93%
NVCT Nuvectis Pharma	30.52%
URGN Urogen Pharma	5.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IOVA Iovance Biotherapeutics	500	333.93 million	299.54 million	Optionable
NUVB Nuvation Bio	60	340.26 million	238.42 million	Optionable
NVCT Nuvectis Pharma	8	20.89 million	14.52 million	Not Optionable
URGN Urogen Pharma	200	46.11 million	43.76 million	Optionable

NVCT, URGN, NUVB, and IOVA Headlines

Recent News About These Companies

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGN

June 27 at 10:00 AM | prnewswire.com

Urogen Pharma (NASDAQ:URGN) Trading Down 5.3% - Time to Sell?

June 24, 2025 | marketbeat.com

Urogen Pharma (NASDAQ:URGN) Receives Consensus Recommendation of "Buy" from Analysts

June 24, 2025 | americanbankingnews.com

Urogen Pharma (NASDAQ:URGN) Given Average Recommendation of "Buy" by Brokerages

June 24, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGN

June 23, 2025 | globenewswire.com

Lowey Dannenberg Notifies UroGen Pharma Ltd. (â€œUroGenâ€ or the â€œCompanyâ€) (NASDQ: URGN) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $50,000 in Losses to Contact the Firm

June 23, 2025 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGN

June 22, 2025 | prnewswire.com

Stocks With Rising Relative Price Strength: UroGen Pharma

June 20, 2025 | msn.com

HC Wainwright Has Negative View of Urogen Pharma Q2 Earnings

June 20, 2025 | americanbankingnews.com

Urogen Pharma (NASDAQ:URGN) Trading 10.3% Higher - Here's What Happened

June 18, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGN

June 18, 2025 | globenewswire.com

HC Wainwright Decreases Earnings Estimates for Urogen Pharma

June 18, 2025 | marketbeat.com

Urogen Pharma (NASDAQ:URGN) Raised to "Buy" at HC Wainwright

June 18, 2025 | americanbankingnews.com

H.C. Wainwright Sees Billion Dollar Potential in UroGen’s New Therapy

June 17, 2025 | msn.com

UroGen Pharma (NASDAQ:URGN) Trading Down 7.7% - Time to Sell?

June 17, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGN

June 17, 2025 | prnewswire.com

UroGen Pharma Ltd. (NASDAQ:URGN) Short Interest Down 29.9% in May

June 17, 2025 | marketbeat.com

URGN SHAREHOLDER ALERT: BFA Law Reminds UroGen Pharma Ltd. Investors of Upcoming July 28 Class Action Deadline - Contact The Firm if You Suffered Losses

June 16, 2025 | accessnewswire.comA

Investors who lost money on UroGen Pharma Ltd.(URGN) should contact Levi & Korsinsky about pending Class Action - URGN

June 16, 2025 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors With Losses on Their Investment in UroGen Pharma Ltd. of Class Action Lawsuit And Upcoming Deadlines - URGN

June 16, 2025 | accessnewswire.comA

UroGen Pharma (NASDAQ:URGN) Sees Large Volume Increase Following Analyst Upgrade

June 16, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVCT, URGN, NUVB, and IOVA Company Descriptions

Iovance Biotherapeutics NASDAQ:IOVA

$1.69 -0.05 (-2.87%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$1.72 +0.03 (+1.48%)

As of 06/27/2025 07:57 PM Eastern

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Nuvation Bio NYSE:NUVB

$1.94 -0.03 (-1.42%)

Closing price 06/27/2025 03:59 PM Eastern

Extended Trading

$1.94 +0.00 (+0.15%)

As of 06/27/2025 07:59 PM Eastern

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.

Nuvectis Pharma NASDAQ:NVCT

$7.55 -0.16 (-2.08%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$8.00 +0.45 (+6.01%)

As of 06/27/2025 07:37 PM Eastern

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.

Urogen Pharma NASDAQ:URGN

$13.49 +0.38 (+2.90%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$13.62 +0.13 (+0.93%)

As of 06/27/2025 07:50 PM Eastern

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time